Business Wire Industry News

Friday, March 22, 2019

Titan Medical to Webcast Business Update Conference Call on March 28, 2019

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that management will webcast a conference call on Thursday, March 28 at 4:30 p.m. ET to provide a business update on the Company and its SPORT Surgical System. Speakers on the call will include David J. McNally, Chief Executiv

Thursday, March 21, 2019

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for year ending December 31, 2018. “IMV made significant advances in 2018,” said Frederic Ors, Chief Executive Officer. “Foundational changes, including shifting the name of the corporation to IMV and listing on Nasdaq, are enabling us to access to a larger pool of investors and allow us to better communicate our value prop

Thursday, March 21, 2019

Titan Medical Closes Public Offering

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce the closing of its previously announced public offering (the “Offering”) pursuant to an agency agreement dated March 18, 2019 between the Company and Bloom Burton Securities Inc. (the “Agent”). The Company closed

Thursday, March 21, 2019

Novanta to Present at Needham & Company 18th Annual Healthcare Conference on Tuesday, April 9, 2019

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the Needham & Company 18th Annual Healthcare Conference on Tuesday, April 9, 2019, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipmen

Thursday, March 21, 2019

Drug-Free Wireless Pain Relief Neurostimulator Changing Lives for Sufferers of Chronic Pain

BLAINVILLE, Quebec--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/BackPain?src=hash" target="_blank"gt;#BackPainlt;/agt;--Statistics Canada says six million people across the country suffer from chronic pain, meaning about 20 per cent of the population is affected. Everyone knows someone suffering from chronic pain and how debilitating it can be, but neurostimulation is changing many lives and offering a drug free alternative for pain management. While implantable neurostimulation has been approved by Health Canada for a decades, what’s different about Stimwave is the small siz

Tuesday, March 19, 2019

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Recent Highlights Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims which have the potential to cover voclosporin’s method of use and dosing protocol for lup

Tuesday, March 19, 2019

Titan Medical Announces Filing of Final Prospectus

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce that yesterday it filed and was receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Uni

Monday, March 18, 2019

Dr Joshua Dunaief MD, Renowned Age-Related Macular Degeneration Clinician and Researcher, Joins Mperia Therapeutics Inc. Clinical Advisory Board

MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/amorchem?src=hash" target="_blank"gt;#amorchemlt;/agt;--Dr. Joshua Dunaief, PhD, MD, the Adele Niessen Professor of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, USA, joins the Clinical Advisory Board (CAB) of Mperia Therapeutics Inc. “A front-line Age-Related Macular Degeneration (AMD) clinician for two decades, combined with a stellar research reputation around oxidative stress in the eye, means Dr Dunaief is the perfect final appointee to our CAB as we finalize our clinical Phase 1 and 2 plans,” state

Friday, March 15, 2019

Enigma Biomedical Group Signs License Agreement with Merck for Novel MK-6884 Imaging Agent

TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884, an early stage investigational imaging agent developed by Merck for use in Positron Emission Tomography (PET) scans to measure cholinergic tone change in vivo. MK-6884 has potential applications as an imaging agent across multiple neurodegenerative diseases. As part of the agreement